Magnetic Resonance - Technology Information Portal Welcome to MRI Technology
Info
  Sheets

Out-
      side
 



 
 'Contrast' 
SEARCH FOR    
 
  2 3 5 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Result : Searchterm 'Contrast' found in 43 terms [] and 326 definitions []
previous     61 - 65 (of 369)     next
Result Pages : [1 2 3 4 5 6 7 8 9]  [10 11 12 13 14 15 16 17 18 19 20 ... ]
Searchterm 'Contrast' was also found in the following services: 
spacer
News  (140)  Resources  (28)  Forum  (72)  
 
Paramagnetic Chemical Exchange Saturation TransferInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.
 
(PARACEST) The alteration of the proton density or total water signal changes contrast and can be detected by the MRI scanner. Paramagnetic chemical exchange saturation transfer contrast agents are based upon the magnetization transfer mechanism.
Lanthanide ion complexes formed with tetra-amide based ligands display unusually slow water exchange kinetics and this feature may be used to alter image contrast by applying a selective presaturation pulse in an imaging sequence. This results in chemical exchange saturation transfer (CEST) from the lanthanide-bound water to bulk water thereby altering image contrast.
Chemical Exchange Saturation Transfer (CEST) agents are a class of contrast agents that could potentially revolutionize the MRI field because of their improved sensitivity and can have a great impact on functional magnetic resonance imaging.
spacer
 
Further Reading:
  Basics:
Multimodal Nanoparticles for Quantitative Imaging(.pdf)
Tuesday, 13 December 2011   by alexandria.tue.nl    
  News & More:
New Brain Imaging Technique Identifies Previously Undetected Epileptic Seizure Sites
Friday, 13 November 2015   by www.newswise.com    
Non-invasive Imaging Method For Diagnosing Osteoarthritis Developed
Friday, 15 February 2008   by www.sciencedaily.com    
Searchterm 'Contrast' was also found in the following services: 
spacer
Radiology  (106) Open this link in a new windowUltrasound  (149) Open this link in a new window
Primovistâ„¢InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Primovist™ (U.S brand name Eovist®) is a highly specific MRI contrast agent for the imaging, detection and characterization of liver conditions, including liver tumors, cysts, as well as other malignant and benign lesions. It is a water-soluble ethoxybenzyl derivative of Gd-DTPA. This compound is taken up by the hepatocytes (approximately 30% of the dose goes to the hepatocytes) and is equally excreted renal and biliary in humans.
Primovist™ brightens the signal of T1 weighted MR images immediately after contrast administration. Dynamic scanning and imaging of the accumulation phase (best after 20 min.) can also be performed after bolus injection of Primovistâ„¢. The hepatocytes uptake will increase the signal intensity of normal liver parenchyma. This results in improved lesion-to-liver contrast because malignant tumors (metastases, the majority of hepatocellular carcinomas) do not contain either hepatocytes or their functioning is hampered.

WARNING: Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.
Drug Information and Specification
NAME OF COMPOUND
Gadoxetic acid disodium, Gd-EOB-DTPA
CENTRAL MOIETY
Gd2+
CONTRAST EFFECT
T1, Predominantly positive enhancement
Short T1-relaxation time
PHARMACOKINETIC
50% hepatobiliary, 50% renal excretion
884 mosm/kgH2O
CONCENTRATION
0.25 mol/L
DOSAGE
12,5 - 25 µmol/kg
PREPARATION
Finished product
INDICATION
Liver lesions
DEVELOPMENT STAGE
for sale
DISTRIBUTOR
See below
PRESENTATION
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE
NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!
Distribution Information
TERRITORY
TRADE NAME
DEVELOPMENT
STAGE
DISTRIBUTOR
EU
Primovistâ„¢
for sale
spacer

• View the DATABASE results for 'Primovist™' (7).Open this link in a new window

 
Further Reading:
  Basics:
New MRI liver contrast agent Primovist® approved in EU
Thursday, 30 September 2004   by www.secinfo.com    
New MRI Liver Contrast Medium
Wednesday, 13 October 2004   by www.hospimedica.com    
Important Drug Warning for Gadolinium-Based Contrast Agents
Wednesday, 12 September 2007   by www.ismrm.org    
MAGNETIC RESONANCE IMAGING OF FOCAL LIVER LESIONS(.pdf)
2002
  News & More:
Comparison of liver scintigraphy and the liver-spleen contrast in Gd-EOB-DTPA-enhanced MRI on liver function tests
Thursday, 18 November 2021   by www.nature.com    
EMA's final opinion confirms restrictions on use of linear gadolinium agents in body scans
Friday, 21 July 2017   by www.ema.europa.eu    
FDA Drug Safety Communication: FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body; requires new class warnings
Tuesday, 19 December 2017   by www.fda.gov    
Gadolinium-containing contrast agents: removal of Omniscan and iv Magnevist, restrictions to the use of other linear agents
Friday, 5 January 2018   by www.gov.uk    
MRI Resources 
Mobile MRI - Image Quality - Pacemaker - Equipment - Abdominal Imaging - Non-English
 
ProHance®InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
ProHance® consists of a nonionic gadolinium complex (Gadoteridol) used as a paramagnetic MR contrast agent.
ProHance® provides contrast enhancement of the brain, spine and surrounding tissues resulting in improved visualization (compared with unenhanced MRI) of lesions with abnormal vascularity or those thought to cause a disruption of the normal blood brain barrier. ProHance® can also be used for whole body contrast enhanced MRI including the head, neck, liver, breast, musculoskeletal system and soft tissue pathologies.

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.

See Gadoteridol.
Drug Information and Specification
NAME OF COMPOUND
Gadoteridol, Gd-HP-DO3A
CENTRAL MOIETY
Gd2+
CONTRAST EFFECT
T1, Predominantly positive enhancement
r1=3.7, r2=4.8, B0=1.0T
PHARMACOKINETIC
Intravascular, extracellular, renal excretion
630 mosm/kgH2O
CONCENTRATION
0.5 mol/L, 279.3mg/ml
DOSAGE
0.1 mmol Gd/kg
PREPARATION
Finished product
INDICATION
Neuro/whole body
DEVELOPMENT STAGE
For sale
DISTRIBUTOR
See below
PRESENTATION
Vials of 5, 10, 15 and 20 mL
Glass syringes of 5, 10, 15 and 17 mL
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE
NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!
Distribution Information
TERRITORY
TRADE NAME
DEVELOPMENT
STAGE
DISTRIBUTOR
USA
EU
ProHance®
for sale
Australia
ProHance®
for sale
Japan
ProHance®
for sale
spacer

• View the DATABASE results for 'ProHance®' (6).Open this link in a new window

 
Further Reading:
  Basics:
Important Drug Warning for Gadolinium-Based Contrast Agents
Wednesday, 12 September 2007   by www.ismrm.org    
Prohance Product Information
   by www.drugs.com    
  News & More:
RSNA Statement on Gadolinium-Based MR Contrast Agents
Thursday, 1 February 2018   by www.rsna.org    
Spurious Hypocalcemia After Omniscan- or OptiMARK-Enhanced Magnetic Resonance Imaging: An Algorithm for Minimizing a False-Positive Laboratory Value
October 2004   by www.findarticles.com    
FDA Drug Safety Communication: FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body; requires new class warnings
Tuesday, 19 December 2017   by www.fda.gov    
EMA's final opinion confirms restrictions on use of linear gadolinium agents in body scans
Friday, 21 July 2017   by www.ema.europa.eu    
Searchterm 'Contrast' was also found in the following services: 
spacer
News  (140)  Resources  (28)  Forum  (72)  
 
Vasovistâ„¢InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Vasovistâ„¢ is an albumin-targeted intravascular contrast agent. It is indicated for contrast enhanced MR angiography (CE-MRA) for the visualization of abdominal or limb vessels in patients with suspected or known vascular disease. After IV injection, Vasovistâ„¢ binds reversibly to human albumin in plasma, which results in long-lasting increased relaxivity. Imaging from 5 to 50 min is possible. A small unbound portion is, by glomerular filtration, eliminated by the kidneys.
AngioMARK® was the formerly trade name and MS-325 the research name. Currently the phase III clinical trials are completed to determine its efficacy for peripheral vascular disease and coronary artery disease.
In the U.S., EPIX received an approvable letter from the U.S. Food and Drug Administration (FDA) for Vasovistâ„¢ in January 2005. In 2009, Epix Pharmaceuticals has sold the U.S., Canadian and Australian rights for its blood pool agent (now named ABLAVARâ„¢), to Lantheus Medical Imaging, Inc..

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or the liver transplantation period.

See also MRI Safety.
Drug Information and Specification
NAME OF COMPOUND
Diphenylcyclohexyl phosphodiester-Gd-DTPA, gadofosveset trisodium, MS-325
CENTRAL MOIETY
Gd2+
CONTRAST EFFECT
T1, predominantly positive enhancement
20-45 mmol-1sec-1, Bo=0,47T
PHARMACOKINETIC
Intravascular, short elimination half life
825 mOsmol/kg H2O
CONCENTRATION
244 mg/mL, 0.25mmol/mL
DOSAGE
0.12 mL/kg, 0.03 mmol/kg
PREPARATION
ready to use
DEVELOPMENT STAGE
approved
DISTRIBUTOR
See below
PRESENTATION
10 mL vials
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE
NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!
Distribution Information
TERRITORY
TRADE NAME
DEVELOPMENT
STAGE
DISTRIBUTOR
EU
Vasovistâ„¢
?
?
North America, Australia
for sale
spacer

• View the DATABASE results for 'Vasovist™' (7).Open this link in a new window

 
Further Reading:
  Basics:
EPIX Medical's new multimedia Web site features AngioMARK images in 3D
Friday, 5 March 1999
MRI technology combined with contrast agent optimizes diagnosis of cardiovascular disease
1999
Searchterm 'Contrast' was also found in the following services: 
spacer
Radiology  (106) Open this link in a new windowUltrasound  (149) Open this link in a new window
ABLAVARâ„¢InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.
 
ABLAVAR™ (formerly named Vasovistâ„¢) is a blood pool agent for magnetic resonance angiography (MRA), which opens new medical imaging possibilities in the evaluation of aortoiliac occlusive disease (AIOD) in patients with suspected peripheral vascular disease.
ABLAVARâ„¢ binds reversibly to blood albumin, providing imaging with high spatial resolution up to 1 hour after injection, due to its high relaxivity and to the long lasting increased signal intensity of blood.
As with other contrast media: the possibility of serious or life-threatening anaphylactic or anaphylactoid reactions, including cardiovascular, respiratory and/or cutaneous manifestations, should always be considered.

WARNING:
NEPHROGENIC SYSTEMIC FIBROSIS
Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.

See also Cardiovascular Imaging, Adverse Reaction, Molecular Imaging, and MRI Safety.
Drug Information and Specification
NAME OF COMPOUND
Diphenylcyclohexyl phosphodiester-Gd-DTPA, gadofosveset trisodium, MS-325
CENTRAL MOIETY
Gd2+
CONTRAST EFFECT
T1, predominantly positive enhancement
20-45 mmol-1sec-1, Bo=0,47T
PHARMACOKINETIC
Intravascular
825 mOsmol/kg H2O
CONCENTRATION
244 mg/mL, 0.25mmol/mL
DOSAGE
0.12 mL/kg, 0.03 mmol/kg
PREPARATION
ready to use
DEVELOPMENT STAGE
FDA approved
DISTRIBUTOR
See below
PRESENTATION
10 mL vials
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE
NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!
Distribution Information
TERRITORY
TRADE NAME
DEVELOPMENT
STAGE
DISTRIBUTOR
EU
Approved
USA, Canada, Australia
ABLAVARâ„¢
Approved
spacer

• View the DATABASE results for 'ABLAVAR™' (3).Open this link in a new window


• View the NEWS results for 'ABLAVARâ„¢' (1).Open this link in a new window.
 
Further Reading:
  Basics:
Ablavar Prescribing Information
   by www.ablavar.com    
  News & More:
The first FDA-approved blood-pool MR agent offers additional time for imaging and possibly some new applications
Thursday, 1 July 2010   by www.radiologytoday.net    
MRI Resources 
Implant and Prosthesis - Mass Spectrometry - Supplies - Colonography - Image Quality - Used and Refurbished MRI Equipment
 
previous      61 - 65 (of 369)     next
Result Pages : [1 2 3 4 5 6 7 8 9]  [10 11 12 13 14 15 16 17 18 19 20 ... ]
 Random Page
 
Share This Page
FacebookTwitterLinkedIn

MR-TIP    
Community   
User
Pass
Forgot your UserID/Password ?    



New acceleration techniques will :
reduce scan times 
cause artifacts 
increase expenses 
be useful if you have a lot of experience 
doesn't do much 
never heard of 

Look
      Ups





MR-TIP.com uses cookies! By browsing MR-TIP.com, you agree to our use of cookies.

Magnetic Resonance - Technology Information Portal
Member of SoftWays' Medical Imaging Group - MR-TIP • Radiology-TIP • Medical-Ultrasound-Imaging • 
Copyright © 2003 - 2024 SoftWays. All rights reserved. [ 29 March 2024]
Terms of Use | Privacy Policy | Advertising
 [last update: 2024-02-26 03:41:00]